Infections in Skeletal Prosthesis and Allografts



Infections in Skeletal Prosthesis and Allografts


Ilker Uçkay

Leonardo Pagani

Axel Gamulin

Daniel P. Lew



INTRODUCTION

Millions of orthopedic implant procedures are performed worldwide each year. The safety and biocompatibility of these devices are good and only 10% of patients experience complications during their lifetime. After loosening of the prosthesis (Figure 40.1), infection is the most common cause of complications. At present, the lifetime infection rate is thought to be 0.5% to 1% for primary total hip arthroplasty, 0.5% to 2% for primary knee replacement, and <1% for shoulder replacement (1,2). Even though the incidence has fallen steadily, the absolute number is rising because of the increase in the number of the procedures performed. For the United States alone, it is projected that ˜4 million artificial joints will be implanted each year by 2030 (3). Thus, the number of prosthetic joint infections is expected to increase. The economic burden of healthcare-associated infection (HAI) with septic prosthetic joints is very high. The cost to treat patients with hip or knee prosthetic osteomyelitis has been calculated to be 5.3- and 7.2-fold higher, respectively, than the primary operations (4).


MUSCULOSKELETAL ALLOGRAFTS

Allografts in orthopedics are gaining momentum. In the United States, ˜1 million musculoskeletal allografts are currently distributed by tissue banks (5) compared to 350,000 in 1990 (6). Processed tissue allografts are not necessarily sterile and may result in viral or bacterial infections. Among patients who had surgery for bone tumor and revision hip arthroplasty, Tomford et al. reported a 5% and 4% incidence, respectively, of infection related to the use of allografts (7). In a series of 945 patients who received cadaveric allografts, Mankin et al. reported 7.9% primary infections (8).


PATHOGENESIS

The usual mechanism involved is the introduction of microorganisms during the operative procedure as the freshly implanted biomaterial is highly susceptible to contamination. It is usually admitted that most joint infections are acquired in the operation theater. Arguments to support this are the efficacy of perioperative antibiotic prophylaxis, laminar flow in the operating room, and the similarity between skin flora and the pathogens that cause prostheses infections (2). Moreover, during the early postimplantation period when superficial infections can develop, the fascial layers have not healed and the deep, periprosthetic tissue is not protected by the usual physical barriers. Any factor or event that delays wound healing increases the risk of infection: ischemic necrosis; hematomas; and, more directly, wound sepsis or suture abscesses. Late infections may emerge after 2 years of pain-free mobility (≥15% of infections) and are mostly attributed to hematogenous seeding with selective persistence of the microorganisms in the joint (1,9).


MICROORGANISMS

Virtually any microorganism can cause prosthetic joint infection. Data from several series indicate that a single pathogen can be identified in only about two-thirds of cases (10). The predominant microorganisms are Staphylococcus sp. (˜50% in several series), evenly divided between S. epidermidis and S. aureus. Aerobic streptococci are responsible for a significant group of infections (between 10% and 20% in different series), followed by gram-positive organisms ordinarily considered as “contaminants” of cultures, such as Corynebacterium spp., Propionibacterium spp., and Bacillus spp. Gram-negative aerobic bacilli have been identified in some series in ≤25% of cases, but anaerobes usually do not account for >10% of all pathogens. Among arthroplasty patients with solid organ transplantations, more atypical pathogens such as mycobacteria may occasionally be observed (11). In up to 10% of cases, no organisms can be detected.

Among allografts, gram-positive bacteria are equally the most frequent organism associated with infection (12). Microorganisms, such as Clostridium spp., have become a concern (13). In 2003, Malinin et al. showed that 8.1% of donor blood, marrow, and musculoskeletal samples grew clostridia, mainly C. sordellii, among 795 donors in the United States (10).


ROLE OF THE FOREIGN BODY AND BIOFILMS

Attachment of bacteria to a prosthetic joint is a critical first step in the pathogenesis of virtually all foreign body-associated infections. A subcutaneous foreign body reduces the inoculum of S. aureus required to induce infection by more than 100,000-fold to as few as 100 colony-forming units (14). In addition, the interaction of neutrophils with the foreign body can induce a neutrophil defect that may enhance the susceptibility to infection (15). Bacteria embedded deeply within
the biofilm are metabolically inactive or in various stages of dormancy, thus protected from host defenses, such as phagocytes, and highly resistant to antimicrobial agents (16). The microenvironment within a biofilm may also adversely affect diffusion of antimicrobial agents. Soon after a biofilm is established, the susceptibility of bacteria to antimicrobial agents often shows a logarithmic decline. With an infection of >1-month duration, it has been postulated that the biofilm has progressed to such a degree that cure with prosthetic retention is less achievable than with resection. In addition, ultrahigh molecular weight polyethylene particles emitted by prosthesis material seem to add to the inhibition of the neutrophil antibacterial activity (17).






Figure 40.1. Aseptic loosening of a left hip prosthesis due to metallosis without proof of infection. Note the radiologic signs of dark areas around the lateral shaft. (Image obtained in a 45-year-old man, University Hospitals of Geneva, Geneva, Switzerland; published with permission of the patient).





Jun 16, 2016 | Posted by in INFECTIOUS DISEASE | Comments Off on Infections in Skeletal Prosthesis and Allografts

Full access? Get Clinical Tree

Get Clinical Tree app for offline access